Surface-specific bone formation effects of osteoporosis pharmacological treatments

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Current anti-osteoporotic pharmacological treatments reduce fracture risk in part by altering bone remodeling/modeling. These effects can manifest on any or all of the bone envelopes-periosteal, intracortical, and trabecular/ endocortical-each of which has unique effects on the biomechanical properties of bone. The purpose of this review is to provide an overview of how the most common FDA-approved anti-osteoporosis agents [bisphosphonates, estrogen/hormone replacement therapy, selective estrogen receptor modulators (SERMs), and parathyroid hormone (PTH)] affect tissue-level remodeling/modeling on each of the bone surfaces. Iliac crest biopsy data, the only means of assessing surface-specific bone formation in humans, exist for all of these agents although they predominately focus on trabecular/endocortical surfaces. Data from pre-clinical animal models provide an essential complement to human studies, particuarily for changes on periosteal surfaces and within the intracortical envelope. Although all of the anti-catabolic agents (estrogen replacement therapy, SERMs, bisphosphonates) exert positive effects on the various bone surfaces, the bisphosphonates produce the unique biomechanical combination of allowing normal periosteal expansion while limiting remodeling-induced bone loss on intracortical and trabecular/endocortical surfaces. PTH, the only FDA-approved anabolic agent, exerts biomechanically favorable alterations though enhanced trabecular/endocortical surface activity while also stimulating periosteal expansion. Through understanding how current and future anti-osteoporotic agents influence surface-specific bone activity we will move one step closer to developing agents that could potentially target a particular bone surface.

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalClinical Reviews in Bone and Mineral Metabolism
Volume6
Issue number1-2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Osteogenesis
Osteoporosis
Pharmacology
Bone and Bones
Diphosphonates
Selective Estrogen Receptor Modulators
Estrogen Replacement Therapy
Bone Remodeling
Parathyroid Hormone
Therapeutics
Anabolic Agents
Hormone Replacement Therapy
Animal Models
Biopsy

Keywords

  • Bisphosphonates
  • Estrogen/hormone replacement therapy
  • Parathyroid hormone
  • Selective estrogen receptor modulators (SERMs)

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Surface-specific bone formation effects of osteoporosis pharmacological treatments. / Allen, Matthew R.

In: Clinical Reviews in Bone and Mineral Metabolism, Vol. 6, No. 1-2, 01.06.2008, p. 62-69.

Research output: Contribution to journalReview article

@article{7d51239e6263443da50545e55cf32a10,
title = "Surface-specific bone formation effects of osteoporosis pharmacological treatments",
abstract = "Current anti-osteoporotic pharmacological treatments reduce fracture risk in part by altering bone remodeling/modeling. These effects can manifest on any or all of the bone envelopes-periosteal, intracortical, and trabecular/ endocortical-each of which has unique effects on the biomechanical properties of bone. The purpose of this review is to provide an overview of how the most common FDA-approved anti-osteoporosis agents [bisphosphonates, estrogen/hormone replacement therapy, selective estrogen receptor modulators (SERMs), and parathyroid hormone (PTH)] affect tissue-level remodeling/modeling on each of the bone surfaces. Iliac crest biopsy data, the only means of assessing surface-specific bone formation in humans, exist for all of these agents although they predominately focus on trabecular/endocortical surfaces. Data from pre-clinical animal models provide an essential complement to human studies, particuarily for changes on periosteal surfaces and within the intracortical envelope. Although all of the anti-catabolic agents (estrogen replacement therapy, SERMs, bisphosphonates) exert positive effects on the various bone surfaces, the bisphosphonates produce the unique biomechanical combination of allowing normal periosteal expansion while limiting remodeling-induced bone loss on intracortical and trabecular/endocortical surfaces. PTH, the only FDA-approved anabolic agent, exerts biomechanically favorable alterations though enhanced trabecular/endocortical surface activity while also stimulating periosteal expansion. Through understanding how current and future anti-osteoporotic agents influence surface-specific bone activity we will move one step closer to developing agents that could potentially target a particular bone surface.",
keywords = "Bisphosphonates, Estrogen/hormone replacement therapy, Parathyroid hormone, Selective estrogen receptor modulators (SERMs)",
author = "Allen, {Matthew R.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1007/s12018-008-9022-6",
language = "English (US)",
volume = "6",
pages = "62--69",
journal = "Clinical Reviews in Bone and Mineral Metabolism",
issn = "1534-8644",
publisher = "Humana Press",
number = "1-2",

}

TY - JOUR

T1 - Surface-specific bone formation effects of osteoporosis pharmacological treatments

AU - Allen, Matthew R.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Current anti-osteoporotic pharmacological treatments reduce fracture risk in part by altering bone remodeling/modeling. These effects can manifest on any or all of the bone envelopes-periosteal, intracortical, and trabecular/ endocortical-each of which has unique effects on the biomechanical properties of bone. The purpose of this review is to provide an overview of how the most common FDA-approved anti-osteoporosis agents [bisphosphonates, estrogen/hormone replacement therapy, selective estrogen receptor modulators (SERMs), and parathyroid hormone (PTH)] affect tissue-level remodeling/modeling on each of the bone surfaces. Iliac crest biopsy data, the only means of assessing surface-specific bone formation in humans, exist for all of these agents although they predominately focus on trabecular/endocortical surfaces. Data from pre-clinical animal models provide an essential complement to human studies, particuarily for changes on periosteal surfaces and within the intracortical envelope. Although all of the anti-catabolic agents (estrogen replacement therapy, SERMs, bisphosphonates) exert positive effects on the various bone surfaces, the bisphosphonates produce the unique biomechanical combination of allowing normal periosteal expansion while limiting remodeling-induced bone loss on intracortical and trabecular/endocortical surfaces. PTH, the only FDA-approved anabolic agent, exerts biomechanically favorable alterations though enhanced trabecular/endocortical surface activity while also stimulating periosteal expansion. Through understanding how current and future anti-osteoporotic agents influence surface-specific bone activity we will move one step closer to developing agents that could potentially target a particular bone surface.

AB - Current anti-osteoporotic pharmacological treatments reduce fracture risk in part by altering bone remodeling/modeling. These effects can manifest on any or all of the bone envelopes-periosteal, intracortical, and trabecular/ endocortical-each of which has unique effects on the biomechanical properties of bone. The purpose of this review is to provide an overview of how the most common FDA-approved anti-osteoporosis agents [bisphosphonates, estrogen/hormone replacement therapy, selective estrogen receptor modulators (SERMs), and parathyroid hormone (PTH)] affect tissue-level remodeling/modeling on each of the bone surfaces. Iliac crest biopsy data, the only means of assessing surface-specific bone formation in humans, exist for all of these agents although they predominately focus on trabecular/endocortical surfaces. Data from pre-clinical animal models provide an essential complement to human studies, particuarily for changes on periosteal surfaces and within the intracortical envelope. Although all of the anti-catabolic agents (estrogen replacement therapy, SERMs, bisphosphonates) exert positive effects on the various bone surfaces, the bisphosphonates produce the unique biomechanical combination of allowing normal periosteal expansion while limiting remodeling-induced bone loss on intracortical and trabecular/endocortical surfaces. PTH, the only FDA-approved anabolic agent, exerts biomechanically favorable alterations though enhanced trabecular/endocortical surface activity while also stimulating periosteal expansion. Through understanding how current and future anti-osteoporotic agents influence surface-specific bone activity we will move one step closer to developing agents that could potentially target a particular bone surface.

KW - Bisphosphonates

KW - Estrogen/hormone replacement therapy

KW - Parathyroid hormone

KW - Selective estrogen receptor modulators (SERMs)

UR - http://www.scopus.com/inward/record.url?scp=58149103067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149103067&partnerID=8YFLogxK

U2 - 10.1007/s12018-008-9022-6

DO - 10.1007/s12018-008-9022-6

M3 - Review article

AN - SCOPUS:58149103067

VL - 6

SP - 62

EP - 69

JO - Clinical Reviews in Bone and Mineral Metabolism

JF - Clinical Reviews in Bone and Mineral Metabolism

SN - 1534-8644

IS - 1-2

ER -